Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Volumn 27, Issue 5, 2012, Pages 1942-1949

  Ketteler, Markus ^a   Martin, Kevin J ^b   Cozzolino, Mario ^b   Goldsmith, David ^b   Sharma, Amit ^b   Khan, Samina ^b   Dumas, Emily ^b   Amdahl, Michael ^b   Marx, Steven ^b   Audhya, Paul ^b  

^a KLINIKUM COBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT; CALCIMIMETIC AGENT; CINACALCET; ERGOCALCIFEROL; NAPHTHALENE DERIVATIVE; PARICALCITOL; VITAMIN D;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MANAGEMENT; DOSE RESPONSE; DRUG COMBINATION; FEMALE; HUMAN; KIDNEY DISEASE; MALE; MIDDLE AGED; MULTICENTER STUDY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CALCIMIMETIC AGENTS; COHORT STUDIES; DISEASE MANAGEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; MALE; MIDDLE AGED; NAPHTHALENES; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; TREATMENT OUTCOME; VITAMIN D;

EID: 84868530411     PISSN: None     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr531     Document Type: Article

References (0)